
Novartis AG
SIX:NOVN

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
82.96
102.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
NOVN
stock under the Base Case scenario is
91.81
CHF.
Compared to the current market price of 96.07 CHF,
Novartis AG
is
Overvalued by 4%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Novartis AG
Historical valuation for NOVN cannot be conducted due to limitations such as insufficient data or other constraints.
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:


Revenue & Expenses Breakdown
Novartis AG
Balance Sheet Decomposition
Novartis AG
Current Assets | 25.1B |
Cash & Short-Term Investments | 7.1B |
Receivables | 8.7B |
Other Current Assets | 9.2B |
Non-Current Assets | 74.8B |
Long-Term Investments | 2.1B |
PP&E | 11.1B |
Intangibles | 52.4B |
Other Non-Current Assets | 9.2B |
Current Liabilities | 31.6B |
Accounts Payable | 4.3B |
Other Current Liabilities | 27.4B |
Non-Current Liabilities | 30B |
Long-Term Debt | 23.2B |
Other Non-Current Liabilities | 6.7B |
Free Cash Flow Analysis
Novartis AG
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Novartis AG
Revenue
|
53.3B
USD
|
Cost of Revenue
|
-12.9B
USD
|
Gross Profit
|
40.3B
USD
|
Operating Expenses
|
-22.9B
USD
|
Operating Income
|
17.4B
USD
|
Other Expenses
|
-4.6B
USD
|
Net Income
|
12.9B
USD
|
NOVN Profitability Score
Profitability Due Diligence
Novartis AG's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

Score
Novartis AG's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
NOVN Solvency Score
Solvency Due Diligence
Novartis AG's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Score
Novartis AG's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NOVN Price Targets Summary
Novartis AG
According to Wall Street analysts, the average 1-year price target for
NOVN
is 104.55 CHF
with a low forecast of 78.78 CHF and a high forecast of 124.95 CHF.
Dividends
Current shareholder yield for NOVN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NOVN
stock under the Base Case scenario is
91.81
CHF.
Compared to the current market price of 96.07 CHF,
Novartis AG
is
Overvalued by 4%.